Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer has always been a difficult problem in clinical practice
because of its young onset age, high aggressiveness, no clear therapeutic target and poor
clinical prognosis. The treatment of triple-negative breast cancer is mainly chemotherapy,
and in order to break the current dilemma, new treatments must be introduced. Immunotherapy
is one of the most high-profile treatments. The KEYNOTE-522 study and Impassion 031 Study
have found that immunotherapy can significantly improve the pCR of patients with triple yin
breast cancer, rate, independent of PD-L1 expression status, and good safety.Cedardenamine is
a histone deacetylation (HDAC) inhibitor developed in China.Many studies suggest that the use
of sidabamine will likely enhance the efficacy of PD-1 / PD-L1 mAb in breast cancer and
expand the use of PD-1 / PD-L1 mAb in the beneficiary population of breast cancer